Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect of Benitec Biopharma Inc. from 30 Sep 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Summary
Benitec Biopharma Inc. quarterly and annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect in USD history and change rate from 30 Sep 2020 to 30 Sep 2025.
  • Benitec Biopharma Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for the quarter ending 30 Sep 2025 was $3,265,000, a 119% decline year-over-year.
  • Benitec Biopharma Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2025 was $46,928,000, a 3.1% decline from 2024.
  • Benitec Biopharma Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2024 was $48,439,000.
  • Benitec Biopharma Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2023 was $1,586,000, a 90% increase from 2022.
Source SEC data
View on sec.gov
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Quarterly (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Quarterly Change (%)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Annual (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Annual Change (%)

Benitec Biopharma Inc. Quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $3,265,000 -$20,241,000 -119% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025 2026 Q1
Q3 2024 $16,976,000 -$6,411,000 -27% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025 2026 Q1
Q3 2023 $23,387,000 +$10,916,000 +88% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2025 Q1
Q3 2022 $12,471,000 +$16,513,000 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2024 Q1
Q3 2021 $4,042,000 -$1,691,000 -72% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2023 Q1
Q3 2020 $2,351,000 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021 2022 Q1

Benitec Biopharma Inc. Annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $46,928,000 -$1,511,000 -3.1% 01 Jul 2024 30 Jun 2025 10-K 22 Sep 2025 2025 FY
2024 $48,439,000 +$50,025,000 01 Jul 2023 30 Jun 2024 10-K 22 Sep 2025 2025 FY
2023 $1,586,000 +$14,122,000 +90% 01 Jul 2022 30 Jun 2023 10-K 26 Sep 2024 2024 FY
2022 $15,708,000 -$25,676,000 -258% 01 Jul 2021 30 Jun 2022 10-K 21 Sep 2023 2023 FY
2021 $9,968,000 01 Jul 2020 30 Jun 2021 10-K 02 Sep 2022 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.